Ongoing Trials

We are currently conducting clinical studies to further evaluate the safety and effectiveness of shockwave therapy in patients with ischemic heart failure.

CAST-HF Registry

Status: Active, Not Recruiting

The CAST-HF Registry will help to gain real-world data in order to prospectively evaluate short and long-term safety and efficacy of direct cardiac shockwave therapy. The main objectives are

to explore potential rare adverse events and knowledge about subgroups,
to identify previously unknown side-effects (related to the medical device),
to monitor the identified side-effects and contraindications,
to identify and analyze emergent risks and
to ensure the continued acceptability of the benefit-risk ratio.

Completed Trials

CAST-HF Trial

Status: Completed

One key finding of the CAST-HF trial is the fact that direct cardiac shockwave therapy resulted in a significant improvement of LVEF at 12 months after the intervention. This results in an improvement of the patients’ physical capacity, increased quality of life and a prolonged life expectancy.